Skip to content

CAPRICOR THERAPEUTICS, INC.: 10-Q filed 2026-08-14

What CAPRICOR THERAPEUTICS, INC. reported in its quarterly report filed 2026-08-14 (fiscal Q2 2026): 41 published measures, 119 facts as tagged in accession 0001104659-26-097294.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q2 2026
Accession
0001104659-26-097294 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CAPRICOR THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-30368,735,835USD
At 2025-12-31355,949,294USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-30122,516,945USD
At 2025-12-3150,157,149USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30246,218,890USD
At 2026-03-31278,702,633USD
At 2025-12-31305,792,145USD
At 2025-06-30104,977,056USD
At 2025-03-31127,645,467USD
At 2024-12-31145,462,336USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3020,935,187USD
At 2025-12-31287,847,312USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-40,733,654USD91
2026-01-01 to 2026-06-30-74,674,999USD181
2026-01-01 to 2026-03-31-33,941,345USD90
2025-04-01 to 2025-06-30-25,910,791USD91
2025-01-01 to 2025-06-30-50,302,385USD181
2025-01-01 to 2025-03-31-24,391,594USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-60,740,078USD181
2025-01-01 to 2025-06-30-26,555,731USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-309,184,644USD181
2025-01-01 to 2025-06-301,183,745USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-2,772,403USD181
2025-01-01 to 2025-06-3069,934USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-203,399,644USD181
2025-01-01 to 2025-06-3038,440,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-379,553,484USD
At 2025-12-31-304,878,485USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3057,926,347shares91
2026-01-01 to 2026-06-3057,681,666shares181
2025-04-01 to 2025-06-3045,709,071shares91
2025-01-01 to 2025-06-3045,673,075shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3057,926,347shares91
2026-01-01 to 2026-06-3057,681,666shares181
2025-04-01 to 2025-06-3045,709,071shares91
2025-01-01 to 2025-06-3045,673,075shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.7USD/shares91
2026-01-01 to 2026-06-30-1.29USD/shares181
2025-04-01 to 2025-06-30-0.57USD/shares91
2025-01-01 to 2025-06-30-1.1USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.7USD/shares91
2026-01-01 to 2026-06-30-1.29USD/shares181
2025-04-01 to 2025-06-30-0.57USD/shares91
2025-01-01 to 2025-06-30-1.1USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,600USD91
2026-01-01 to 2026-06-301,600USD181
2025-04-01 to 2025-06-301,600USD91
2025-01-01 to 2025-06-301,600USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-3036,346,335USD
At 2025-12-3118,312,238USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-42,945,620USD91
2026-01-01 to 2026-06-30-79,718,473USD181
2025-04-01 to 2025-06-30-27,717,534USD91
2025-01-01 to 2025-06-30-52,700,482USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-30242,127,977USD
At 2025-12-31322,939,756USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3032,961,421USD
At 2025-12-3135,836,760USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-303,079,714USD
At 2025-12-311,654,754USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-3042,945,620USD91
2026-01-01 to 2026-06-3079,718,473USD181
2025-04-01 to 2025-06-3027,717,534USD91
2025-01-01 to 2025-06-3052,700,482USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3028,866,292USD91
2026-01-01 to 2026-06-3056,243,204USD181
2025-04-01 to 2025-06-3022,047,254USD91
2025-01-01 to 2025-06-3040,962,826USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3058,108,989shares
At 2025-12-3157,370,909shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3020,935,187USD
At 2025-12-31287,847,312USD
At 2025-06-3023,241,199USD
At 2024-12-3111,286,996USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-163,541USD
At 2025-12-31283,154USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-3088,615,221USD
At 2025-12-3113,537,820USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-3091,045,362USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2026-06-3042,493,750USD
At 2025-12-3123,462,831USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-306,147,415USD
At 2025-12-315,150,593USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-3016,391,869USD
At 2025-12-3115,557,646USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-304,193,195USD
At 2025-12-314,810,841USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2026-06-3012,000,000USD
At 2025-12-3112,000,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-40,732,054USD91
2026-01-01 to 2026-06-30-74,673,399USD181
2025-04-01 to 2025-06-30-25,909,191USD91
2025-01-01 to 2025-06-30-50,300,785USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-74,674,999USD181
2025-01-01 to 2025-06-30-50,302,385USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-40,643,468USD91
2026-01-01 to 2026-06-30-75,121,694USD181
2025-04-01 to 2025-06-30-26,335,144USD91
2025-01-01 to 2025-06-30-49,941,766USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-3014,079,328USD91
2026-01-01 to 2026-06-3023,475,269USD181
2025-04-01 to 2025-06-305,670,280USD91
2025-01-01 to 2025-06-3011,737,656USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-30561,845USD91
2026-01-01 to 2026-06-301,096,515USD181
2025-04-01 to 2025-06-30486,278USD91
2025-01-01 to 2025-06-30891,728USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,096,515USD181
2025-01-01 to 2025-06-30891,728USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,213,566USD91
2026-01-01 to 2026-06-305,045,074USD181
2025-04-01 to 2025-06-301,808,343USD91
2025-01-01 to 2025-06-302,399,697USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,600USD181
2025-01-01 to 2025-06-301,600USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2026-04-01 to 2026-06-30614,675USD91
2026-01-01 to 2026-06-301,229,350USD181
2025-04-01 to 2025-06-30227,201USD91
2025-01-01 to 2025-06-30454,403USD181

Inspect the source

Entity
CAPRICOR THERAPEUTICS, INC. / CIK 0001133869
Captured
2026-09-20T07:41:24.575Z
SEC response SHA-256
b9f947143784aa2a5b7cc0470638338f21bd5664475f1be49c554014f98dbf5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001133869.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))